Though India has built a robust domestic biosimilar market, its international presence and the ability to lower prices as compared to small molecule generics remain limited.
Without widespread access to biosimilars, thousands of cancer patients are losing their battle. Life-saving treatment is not a privilege but a right. The government should understand this.
Contrary to naysayers, the RSS practices what it preaches. It is closer to the Gandhian teaching of improving the individual morally and spiritually to change the external environment.
This is the game every nation is now learning to play. Some are finding new allies or seeing value among nations where they’d seen marginal interest. The starkest example is India & Europe.
COMMENTS